When Skin and Hair Products Say “Clinically Studied”

NutraIngredients published its report on the Council for Responsible Nutrition’s (CRN) inaugural SciComms Connect symposium on October 16, 2026. The event took place on October 6, 2026, in Carlsbad, California and examined how women’s-health research is translated into products and consumer messages.

What assumption was being challenged?

The symposium challenged a familiar leap in product marketing: moving from research on an ingredient to a claim about the finished product. It did not announce a replacement for a medical standard of care. The shift under discussion was toward a closer match between the research and the message reaching women.

In its September 24 preview, NutraIngredients described the central questions as who was studied and what was tested. Needed co-founder and co-CEO Ryan Woodbury cautioned that the studied formulation, dose, population or outcome may differ from what a product’s marketing suggests.

For readers navigating changes in appearance at midlife, that distinction moves attention away from a reassuring scientific label. A useful claim needs a traceable connection between the evidence and the product being sold. Ingredient research remains part of that picture rather than a substitute for every other question.

What should a “clinically studied” claim explain?

The preview’s evidence criteria provide a practical way to read a skin, hair or menopause product claim. The aim is not to make readers judge every technical detail. It is to identify the information a claim needs before it can be meaningful.

• What exactly was tested? Research on an ingredient and research on the finished formulation answer different questions. According to Woodbury’s warning in the preview, an ingredient study does not automatically substantiate the marketed product. A clear explanation should identify which of these was tested rather than leaving the reader to assume that the product on the shelf was the one used in the research.
• Did the studied dose match the marketed dose? The amount used in research is part of the evidence behind a claim. The preview identified a mismatch here as one reason a finding may not transfer to a product. This is a comparison between the study and the claim, not a recommendation to change how much of a product someone uses.
• Who was included? A claim aimed at women should identify the women represented in the research. For a midlife reader, the useful detail is whether the intended population matches the study population. A broad reference to women’s health does not answer a specific question about whether a finding applies to women at the life stage named in the marketing.
• What outcome did the researchers measure? The October event report distinguished physiological biomarkers from clinical benefits. A change in a biological measure and an improvement that matters to a person are not interchangeable. If a product promises an appearance benefit, the relevant question is whether the research measured that benefit rather than a different outcome presented as if it were equivalent.
• How closely does the wording follow the result? Woodbury’s caution covered both “clinically studied” and “clinically proven.” Those phrases need an explanation of the actual finding and its certainty. The reader should be able to connect the claim with the outcome reported in the study without filling in missing steps on the company’s behalf.

Why is hair health a useful test case?

NutraIngredients used hair health to show why an ingredient’s reputation is not the same as evidence for a specific product. Its preview identified hormones alongside stress and nutrition as possible influences. Aging and lifestyle were also part of the picture.

For midlife women, the practical implication is to resist an explanation that turns every hair change into a hormone problem. The question behind a purchase may be about appearance, but the evidence still needs a defined population and a defined outcome.

• A hormone-related story needs more than a hormone-related ingredient. The explanation offered for a product is not the same thing as a demonstrated result. The preview’s stronger evidence standard was a specific formulation tested for the intended outcome in the intended population.
• A narrow finding needs narrow language. When the study measured one outcome, the claim should stay attached to that outcome. A general promise about hair health should not quietly replace the more specific question the research addressed.

That is also a reason to place product claims within a wider understanding of the menopause transition. Appearance deserves thoughtful coverage without becoming a reason to interpret every change through one cause or one purchase.

What did the event reveal about research involving women?

The October 16 report also examined how women are represented in research. It included sports-nutrition examples rather than trials of midlife skin or hair products:

• Representation needs a denominator. USANA’s Kathryn Armstrong cited an analysis of 1,826 sports-nutrition studies in which women accounted for 23% of participants. Keeping the participant figure attached to the named analysis preserves its meaning.
• Participation and useful context are separate questions. Armstrong reported that 14% of studies involving women in the analysis reported menstrual status. Her example directs attention beyond whether women were present to what the research recorded about them.

For a reader assessing a product intended for menopause, the practical lesson is to look for the population description rather than relying on the category printed on the packaging. Research involving women is a starting point for that assessment. It does not remove the need to check the intended life stage and the specific outcome.

Where does this evidence stop?

The reports describe an industry symposium and the views of speakers, not proof that a particular supplement works. They provide no study results establishing that the reviewed hair products improve thinning during perimenopause or menopause. The sports-nutrition figures belong to that field and should not be stretched into a measure of all women’s-health research.

Within those boundaries, the next step is straightforward: look for an explanation that puts the formulation, studied dose and population beside the measured outcome. If those details are absent, the claim remains incomplete rather than becoming a reason to assume either benefit or harm.

Questions about the cause of a personal skin or hair change belong with qualified care. Product evidence can inform that conversation, but reading a marketing claim is not a way to diagnose the change or select an individual treatment.

What did the speakers want communication to change?

Woodbury said responsible communication should explain “who was studied, what was measured and how certain the conclusion is.” In the October report, he described adapting research for different audiences this way: “What changes is the vocabulary, the depth, and the context to match each audience.”

CRN’s Andrea Wong made the organisational point in the September preview. She argued that scientific and regulatory teams should work with innovation and communications teams throughout product development. Her proposal was to bring communication into the process early rather than adding it only after formulation and regulatory work were complete.

That approach places responsibility for a clear explanation with the people developing and marketing the product. Women should not have to repair a vague claim by guessing what the science might have meant.

How should this influence clinical conversations?

For future clinical conversations, the useful shift is from a scientific-sounding label to evidence that matches the product’s formulation, intended users and claimed benefit.

How Refemina helps

Whether a skin or hair claim matches the product being sold is the decision at issue; Refemina takes the discussion from marketing language to evidence-led understanding. For women facing appearance changes alongside aggressive anti-aging messages, its editorial coverage places skin and hair within the wider hormonal transition without treating youth or a supplement as the answer.

Explore Resources

Sources

1. Women's health boom puts science communication under ...
2. Women's health research faces tougher questions at CRN ...